Traws Pharma Announces $3.1 Million ATM Equity Offering Update

On May 22, 2026, Traws Pharma, Inc. filed a Current Report on Form 8-K to provide updates regarding its At The Market (ATM) Offering Agreement with Citizens JMP Securities, LLC. Originally entered into on March 10, 2025, the ATM Agreement allows the company to sell shares of common stock with an aggregate sales price of up to $50,000,000. Under the current prospectus supplements, Traws Pharma is offering and selling shares having an aggregate offering price of up to $3,128,399. This specific amount is dictated by the company's current 'baby shelf' limitations under General Instruction I.B.6. of Form S-3. The shares are being issued pursuant to an effective shelf registration statement (No. 333-273081) originally filed in June 2023. The filing includes a legal opinion from Snell & Wilmer L.L.P. confirming that the shares, when issued and paid for, will be validly issued, fully paid, and nonassessable. No clinical trial updates or other material corporate changes were disclosed in this filing.